AbCellera entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology. Under the agreement, Incyte has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive clinical and regulatory milestone payments and royalties on sales of products.

“We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,” said Murray McCutcheon, senior vice president of partnering at AbCellera. “We look forward to working as an extension of Incyte’s team to address complex antibody discovery challenges and accelerate the development of Incyte’s preclinical pipeline of oncology medicines.”

Patrick Mayes, vice president, BioTherapeutics at Incyte said, “This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer. We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology.”